CurveBeam AI Limited (CRVAF) Shareholder/Analyst Call Prepared Remarks Transcript

CurveBeam AI Limited (OTC:CRVAF) opened its 2025 Annual General Meeting on Nov. 26, 2025 with Non‑Executive Chair Robert Lilley introducing the board and senior management, including CEO Greg Brown and CFO Ura Phillip Auckland. Management announced a forthcoming CEO presentation on company progress and noted involvement of current auditors PwC and proposed new auditors BDO; the provided excerpt contains no financial results, guidance, or operational metrics.

Analysis

Market structure: The AGM and auditor transition signal corporate governance actions that typically benefit larger AI/MedTech incumbents (NVDA, MDT, ISRG) via greater pricing power and platform consolidation, while small OTC microcaps like CRVAF face funding and liquidity pressure. Expect near-term M&A arbitrage (small targets acquired) and margin capture by software/compute providers; lending spreads for small healthcare tech issuers should widen 100–300bp if fundraising begins.

Risk assessment: Key tail risks are an adverse audit opinion, restatement or delisting for CRVAF leading to >90% equity loss, or a dilutive capital raise eroding existing holders by 20–60%; these can materialize within 30–90 days around filings. Hidden dependencies include reliance on third‑party compute/AI partners and regulatory approvals (medical device/AI rules) that can delay commercialization by 6–24 months. Catalysts to watch: FY25 audited results, auditor appointment confirmation, and any uplisting/financing announcement within the next 60–90 days.

Trade implications: For liquid exposure favor platform winners: consider a 2–3% tactical overweight in NVDA (AI compute exposure) and 1–2% hedge short in IBB (biotech/spec‑medtech beta) to express consolidation/selection. For CRVAF (OTC:CRVAF) limit speculative allocation to 0.25–0.75% of portfolio size with strict triggers (see decisions). Use 3–6 month call spreads on NVDA (buy ATM, sell 10–15% OTM) to capture upside while capping cost and buy protective puts on any small‑cap basket to limit tail drawdown.

Contrarian angle: The market often underprices the value of a clean auditor change when it precedes restructuring or a financing—if BDO appointment is followed by clear remediation/uplisting steps within 90 days, a rapid 30–100% rerating is plausible for a tightly held OTC name. Conversely, the common mistake is to assume the auditor switch is benign; absent clear operational milestones this is a red flag for dilution. Historical parallels include microcap medtechs that restructured into software plays and were either acquired at multiples or wiped out after failed audits.

Key Decisions for Investors

• Establish a capped speculative long in OTC:CRVAF of 0.25–0.75% of portfolio only after three triggers within 60 days: (1) BDO appointment formally confirmed in regulatory filing, (2) audited FY25 financials released without material weakness, and (3) management presents a clear funding/uplisting timeline. Liquidate immediately if an adverse opinion or accounting restatement is announced or if a financing dilutes existing shareholders by >20%.
• Initiate a 2–3% long position in NVIDIA (NVDA) to play AI compute demand and medtech imaging adoption, paired with a 1–2% short position in iShares Nasdaq Biotechnology ETF (IBB) to hedge biotech/speculative medtech beta; rebalance after 3 months or if NVDA moves +25%/−15% from entry.
• Use options to size asymmetric exposure: buy 3–6 month NVDA call spreads (long ATM, short 10–15% OTM) sized to 1–2% portfolio risk to capture upside; purchase 3–6 month puts on a 5–10 stock small‑cap medtech basket (or a small‑cap healthcare ETF) to cap tail risk, stop-loss portfolio cost at 0.5% absolute drawdown.
• Reduce cash exposure to speculative OTC microcaps and increase allocation to core large-cap medtech/AI leaders by +1–2% over 30 days; monitor credit spreads on high‑yield healthcare names—if HY spreads widen >150bp in 30 days, further cut small‑cap risk by an additional 1–2%.